Alto Neuroscience Phase 2b trial of ALTO-100 for MDD fails primary endpoint

Alto Neuroscience, Inc.

ALTO-100 did not show statistically significant improvement on MADRS vs placebo in biomarker-defined MDD patients.
Favorable safety and tolerability; no new signals; common AEs headache, nausea, abnormal dreams at rates similar to placebo.
ALTO-100 also in Phase 2b for bipolar depression; cash expected to fund operations into 2027 with other readouts in H1 2025.
Company will analyze full dataset to determine next steps for ALTO-100 in MDD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.